One potential explanation for the negative results of combined inhibition therapy using one multi-targeted agent is its effect on inhibition both the VEGFR and EGFR signaling pathways is not as specific as that of single-targeted therapy (e.g. bevacizumab, erlotinib), which may compromise its overall anti-tumor efficacy. This evidence concerns the gene EGFR and neoplasm.